Between 1984 and 1997, 23 consecutive patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in first complete remission were treated with allogeneic bone marrow transplants from HLA-matched siblings. All patients but one were conditioned with fractionated total body irradiation (1320 cGy) and high-dose etoposide (60 mg/kg). One patient received high-dose cyclophosphamide instead of etoposide, and another patient received both drugs. Nine patients died following BMT, two from relapsed leukemia, and seven from transplant-related causes. The 3-year probabilities of disease-free survival and relapse are 65% and 12%, respectively. For patients transplanted after 1992, these probabilities are 81% (48-95%, 95% confidence interval) and 11% (2-50%), respectively. The relatively low relapse rate in this group of patients compared to published reports may reflect the enhanced antileukemic activity of etoposide in combination with FTBI compared to other conditioning regimens. The enhancement in overall survival for patients transplanted after 1992 may reflect improvements in supportive care, in particular, the prophylaxis of serious fungal and viral infections.
Introduction
The Philadelphia chromosome (Ph) is found in 20-30% of adults and 3-5% of children with acute lymphoblastic leukemia (ALL). [1] [2] [3] Patients with Ph+ ALL have an extremely poor prognosis for long-term survival. 4 Although the ability to achieve a first complete remission (CR) is not significantly reduced in Ph+ ALL, the durability of these remissions with standard and intensified chemotherapy regimens is extremely limited. 5 Allogeneic bone marrow transplantation (BMT) has been utilized as a post-induction therapy to try to improve disease-free survival (DFS) for these patients. 6 The IBMTR has reported a 38% disease-free survival rate for patients transplanted with Ph+ ALL in first CR. 7 The bcr-abl oncogene, which is the molecular counterpart of the Ph chromosome, is detected in two variant forms, either p190 or p210, by sensitive polymerase chain reaction (PCR) techniques. In adults with Ph+ ALL, the p190 form is detected in about 50% of cases, whereas in pediatric cases, the p190 is the dominant variant and is detected in about 90% of cases. 2, 8 Generally, there are no significant differences in the biology or response to chemotherapy between p190+ vs p210+ ALL. 9 However, a recent report on allogeneic BMT for Ph+ ALL suggested that the expression of p190 bcr-abl after BMT was asso- ciated with a significantly increased risk of relapse compared to the expression of the p210 variant. 10 We have previously published our results for a group of 17 patients in first CR with a 2-year DFS of 46 ± 25%. 11 We now report the results for a larger group of 23 patients (including the original 17 patients) who have been followed for a median of 3 years (range 1.3-10.2 years). All patients but one were conditioned with fractionated total body irradiation (FTBI) and high-dose etoposide. Risk factors such as bcr-abl PCR results, cytogenetic findings in addition to the Ph chromosome, and year of transplant are reviewed.
Patients and methods

Patient characteristics
The patient characteristics are presented in Table 1 . There were 14 male and nine female patients ranging in age from 6 to 44 years (median 30 years). All patients were transplanted while in first CR. The patients were treated with a variety of induction chemotherapy regimens, using standard dosages and schedules, often at outside institutions before they were referred for BMT. For the majority of patients, a combination of vincristine (V), prednisone (P), daunorubicin (D), and Lasparaginase (L-asp) was used to induce a remission. Some patients received other drugs in combination such as cyclophosphamide (CY), cytosine arabinoside (Ara-C), and 6-mercaptopurine (6-MP). The 23 patients received the following combinations for induction chemotherapy: V/D/P in three; V/D/P/L-asp in nine; D/Ara-C/CY/6-MP/L-asp in two, Ara-C/idarubicin in one; other combinations of V/D (±Ara-C, CY) in eight. Two patients (UPN 893 and 1062) received highdose Ara-C as part of the induction regimen. Eighteen of the 23 patients also received post-remission chemotherapy consisting of oral methotrexate, 6-MP, ± CY or Ara-C. The time from CR to BMT ranged from 20 to 163 days (median 76 days). The date of analysis was 1 April 1998.
Cytogenetic analysis
Cytogenetic studies on pretreatment and follow-up bone marrow samples were performed using standard G-banding with trypsin-Giemsa or trypsin-Wright's staining using the standard methods. Karyotypes were interpreted using International System for Cytogenetic nomenclature (ISCN) criteria. 12 The pretreatment cytogenetic data are presented in Table 2 . Six patients were Ph+ as the sole abnormality at the time of diagnosis and 13 patients had additional chromosomal abnormalities. For four patients the status of additional aberrations at 
Fluorescence in situ hybridization (FISH) analyses
Dual-color FISH analysis was performed as per the manufacturer's recommendations, the Oncor mBCR/ABL probe (Gaithersburg, MD, USA), and the residual methanol:acetic acid fixed chromosome bone marrow suspensions stored at −20°C. The Oncor mBCR/ABL probe detects all bcr-abl translocations, whether translocated at the major or minor breakpoint. A minimum of 500 interphase nuclei was scored per sample. In house validation studies for the mBCR/ABL interphase FISH studies (performed on normal and abnormal samples) indicated a value less than 6% is considered within background limits selected to maximize specificity (sensitivity, 81% with 95% confidence limits of 72-89% and specificity, 93% with 95% confidence limits of 86-97%).
Polymerase chain reaction
The bcr-abl mRNA was detected by PCR pre-BMT and after BMT for the majority of patients. The method for PCR was a single-step amplification of 30-33 rounds as previously described. 13 The sensitivity of this assay was one to three bcrabl-positive cells in 10 5 . Data were available for 17 patients pre-BMT. Five patients expressed the p190 variant, 10 expressed the p210 form (five b3a2 (splice 1) two b2a2 (splice 2), and three both splices), and two were negative. (Samples from these two patients were only available after they had achieved a first CR.) Samples were submitted for PCR analysis after BMT at variable time points for 16 of the 23 patients. For these 16 patients, the number of samples per patient ranged from one to seven with a median of three. The submission of samples was not monitored prospectively, but post-BMT bone marrow aspirations were generally performed around days +30, 100, 180, 365, and yearly thereafter. The compliance with this schedule was quite variable.
Bone marrow transplantation
The conditioning regimen consisted of fractionated total body irradiation (FTBI) 1320 cGy delivered in 11 fractions over 4 days, followed by etoposide (VP16) at 60 mg/kg 14, 15 in 21/23 patients; FTBI followed by CY at 120 mg/kg given over 2 days in one patient; and a combination of FTBI/VP16/CY in one patient. 16 All patients except one received hematopoietic cells in the form of unmanipulated bone marrow from HLA-matched sibling donors. Patient, UPN 936, received G-CSF primed peripheral blood stem cells from her HLA-matched sister. Graftversus-host disease (GVHD) prophylaxis consisted of cyclosporin A (CsA) plus methotrexate (MTX) for three patients; CsA/methylprednisolone (PSE) for eight patients, and CsA/MTX/PSE for 12 patients, as per institutional trials conducted during this time period. [17] [18] [19] Supportive care was provided as previously described. 15 The pre-emptive utilization of ganciclovir based on shell vial positivity from bronchoalveolar lavage or peripheral blood samples was introduced as standard care starting in 1991. 20 Routine fungal prophylaxis with low-dose i.v. amphotericin B at 0.15 mg/kg/day was instituted in 1992. 21 Patients were treated in hepa-filtered isolation rooms until engraftment of neutrophils. All patients were treated on protocols approved by the Institutional Review Boards at City of Hope National Medical Center or at Stanford University Medical Center.
Statistical analysis
The log-rank test was used to determine significant differences in survival curves for the various parameters tested. KaplanMeier plots 22 were used to calculate probabilities of DFS, overall survival (OS), and relapse rates.
Results
Overall and disease-free survival
The median follow-up time for all patients is 34 months (range 0.6-123 months). For living patients, the median follow-up time is 40 months , and for expired patients it is 2 months (0.6-41). In Figure 1 , the Kaplan-Meier plots for DFS and relapse for all patients are displayed. The plot for OS is the same as DFS since both patients who relapsed died from their disease within a short time interval. The probability of 3-year DFS (95% confidence intervals) for all patients is 65% (43-81%), and the probability of relapse is 12% (3-32%). The data comparing the group of patients transplanted before 1992 with those transplanted after 1992 are presented in Figure 2 . There is a significant difference in DFS for these two groups with a 3 year probability of DFS of 81% (48-95%) for the group transplanted after 1992 compared to 45% (20-73%) for the earlier cohort (P = 0.04 by the log-rank test).
Six of the 23 patients developed grade I acute GVHD and three developed grade II-IV acute GVHD. Five patients out of the 17 patients who survived to day +100 developed limited chronic GVHD and six patients developed extensive chronic GVHD. Nine of the 23 patients died -two from relapsed leukemia, one from extensive chronic GVHD, one from a cerebral hemorrhage, and five from various infections (two
Figure 1
Kaplan-Meier plots of probabilities of disease-free survival and relapse for all 23 patients transplanted.
Figure 2
Kaplan-Meier plots of probabilities of disease-free survival for the 12 patients transplanted after 1993 compared to the 11 patients transplanted before 1993. sepsis, one aspergillosis, one CMV pneumonitis, one other pneumonia) ( Table 3) .
Post-transplant relapse
Only two of the 23 patients relapsed -one at day +121 (UPN 744) and one at day +636 (UPN 893). UPN 893 expressed the p190 bcr-abl oncogene, and the other patient (UPN 744) expressed the p210 variant pre-BMT. There was no significant impact for the time from CR to BMT, the inclusion of highdose Ara-C in the induction regimen, or the inclusion of postremission chemotherapy on the risk of relapse or DFS. Both patients had additional chromosome abnormalities pre-BMT . Classic cytogenetics studies were limited on day +636 with only three Ph-negative cells collected for analysis. However, the day +685 marrow identified a Ph+ clone with multiple numerical and structural aberrations. The previous results, which had been negative, were on day +364 for PCR and FISH. A Ph+ clone was observed in UPN 744 on day +107; clinical relapse occurred on day +121. FISH analysis was not performed. The PCR result on day +121 was deemed false negative due to poor RNA integrity (ie the normal abl and ␤-actin mRNA controls were negative). The complete cytogenetics results at the time of relapse after BMT for the two patients who relapsed were as follows: for UPN 893: 46,XY,del(1)(p31.2p36.3),del(3)(p11),t(5;7) (q22;q32), t(9;22)(q34.1;q11.2),−13,add (16) 
Polymerase chain reaction results
The impact of PCR findings was analyzed. Pre-BMT PCR results were available for 17 of the 23 patients. Five patients expressed the p190 splice at some time before BMT; 10 patients expressed the p210 splice (five splice 1, two splice 2, three both splice 1 and 2); and two patients were negative (one of these two patients, UPN 984 had a positive result for splice 1 post-BMT). Nine of these 17 patients were negative at the time of the last analysis just before BMT, and eight were still positive. There were no differences in relapse rates or OS for these two groups of patients.
Ten patients had detectable bcr-abl mRNA by PCR at varying times following BMT. Five patients expressed the p210 form (the latest time point was day +812), four patients the p190 (the latest time point was day +413), and one patient expressed both. None of the patients who expressed the p210 variant relapsed. One of the patients who expressed the p190 variant relapsed. The other patient who relapsed expressed the p210 variant pre-BMT and relapsed cytogenetically 2 weeks before his clinical relapse, but poor quality RNA resulted in a false negative PCR result post-BMT. Nine of 10 patients who were PCR positive at some time after BMT also had acute or chronic GVHD or both. Five of the seven patients who were PCR positive at day +100 or later had chronic GVHD as well (UPNs 456, 893, 934, 936, 1065) ( Table 3) .
Discussion
In this report, we present the results for DFS and relapse rates for a group of patients with Ph+ ALL in first CR treated with allogeneic BMT at two institutions. These results compare favorably to previous reports from the IBMTR, 7 in which a DFS of 38% (23-55%) and a relapse rate of 34% were reported for a similar group of patients. Other centers have reported results that include patients at various stages of disease with lower DFS rates and higher relapse rates than our results. [23] [24] [25] In those reports, most of the patient were conditioned with regimens of TBI/CYT or busulfan/CYT. A group from Germany 23 described their results for 10 patients transplanted for Ph+ ALL from either sibling, matched related, or matched unrelated donors. Seven of these patients were in first CR, and four of the seven received transplants from sibling donors. All patients were conditioned with a regimen of TBI/CYT/VP16. Only one of these four patients who had a sibling donor relapsed, and overall, only two of the 10 patients relapsed. We speculate that the use of high-dose etoposide in the conditioning regimen may be important in explaining the lower relapse rates observed both in our study and the German study compared to the other reports. The young median age of our patients (30 years) may also be a factor in explaining the favorable results. The intensity of the induction and post-remission chemotherapy regimens was not a significant factor in predicting relapse risk.
Since there were only two relapses out of the group of 23 patients, it is difficult to draw meaningful conclusions about risk factors for relapse. Nonetheless, it is of interest that the two relapses occurred in patients who had additional chromosomal changes present at diagnosis besides the Ph+. At the time of relapse, these two patients had multiple new chromosomal aberrations, as is often seen in relapsed leukemia. The appearance of these new abnormalities may have been secondary to the toxicity of the pre-BMT conditioning regimen, or may have reflected clonal evolution of the leukemia. The clinical significance of additional chromosomal changes in Ph+ ALL at presentation has not been discussed in the literature. It would be of interest to see whether other centers or cooperative groups also identify the presence of additional chromosomal changes as a risk factor for these patients.
Again because of the low relapse rate in this group of patients, it is difficult to draw conclusions about the impact of bcr-abl patterns of expression both pre-BMT and post-BMT. Of the two patients who relapsed, one each expressed the p210 or p190 variants before BMT. We cannot confirm the observations of Radich et al 10 who found a significantly increased risk of relapse for patients who expressed the p190 bcr-abl mRNA post-BMT. Other investigators have also reported on the predictive value of PCR positivity after BMT for clinical relapse utilizing either one-step 26 or two-step 27, 28 PCR assays. In our study using a one-step PCR assay, there was a significant incidence of PCR positivity post-BMT with about half the patients expressing p190 and the other half p210 mRNA. Some of the patients were PCR positive at time intervals up to 2 years after BMT, and yet did not relapse. It may be that the level of expression of the p190 bcr-abl mRNA was lower after high-dose etoposide compared to other regimens. Quantitative PCR analysis may be of value in demonstrating differences in absolute levels and/or rates of change of bcr-abl expression after BMTs that utilize different conditioning regimens. Such analyses may better predict clinical relapse as Lin et al 29 reported for patients treated with BMT for chronic myelogenous leukemia. It is also possible that a graft-versus-leukemia effect is responsible for maintaining a clinical remission in these patients with molecular evidence of persistent disease since five of the seven patients who were PCR positive after day +100 had some degree of chronic GVHD. The relapse rate for these patients was extremely low, indicating that PCR positivity post-BMT is not necessarily associated with clinical relapse.
There was a striking difference in survival rates for patients transplanted after 1992 compared to those transplanted before 1992. Only one patient relapsed in each of these two groups. On the other hand, the mortality rate from causes other than relapse was much lower for the more recent cohort of patients. This improvement in treatment-related mortality may reflect the impact of a variety of innovations in supportive care that have been introduced since the early 1990s. Most notable perhaps is the pre-emptive use of ganciclovir in patients with early evidence of activated CMV to prevent the development of CMV pneumonitis. 20 In the past, this complication occurred in about 20% of allogeneic BMT patients, with a mortality rate of close to 100%. In addition, the routine use of low-dose prophylactic intravenous amphotericin B 21 may account for a reduction in mortality due to systemic fungal infections.
The results of this study indicate that allogeneic BMT from matched sibling donors is a very effective treatment for patients with Ph+ ALL in first CR. The inclusion of high-dose etoposide (VP-16) along with FTBI may reduce the risk of relapse and increase survival considerably. The detection of minimal residual disease after BMT by PCR does not necessarily predict a higher risk of relapse. Further studies on the impact of p190 vs p210 bcr-abl expression on BMT outcomes are needed. Quantitative PCR assays may be particularly helpful in determining the significance of bcr-abl positivity after BMT.
